DEPARTMENT OF HEALTH & HUMAN SERVICES



National Institutes of Health Bethesda, Maryland 20892

NOV 7 2016

Christopher P. Wild, Ph.D.
Director, International Agency for Research on Cancer
World Health Organization
150 cours Albert Thomas
69372 Lyon cedex 08, France

Dear Dr. Wild:

Thank you for your recent letter addressed to Dr. Francis S. Collins, Director of the National Institutes of Health (NIH), regarding a letter from Congressman Jason Chaffetz, Chairman of the House Committee on Oversight and Government Reform, concerning the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. As the Acting Director of the National Cancer Institute (NCI), I am responding on behalf of the NIH.

As you know, the NCI has funded the IARC Monographs program under a cooperative agreement through the NIH peer review process since 1982. The IARC Monographs program has been highly regarded within the scientific community for its systematic, rigorous, comprehensive reviews and evaluations of evidence on the carcinogenicity of a wide range of human exposures based on the current state of the science. NCI supports the process the IARC Monographs program uses to make its evaluations of agents and exposures, and recognizes that evaluation results may change over time as additional scientific evidence becomes available.

Thank you for your support.

Sincerely,

Douglas R. Lowy, M.D.

Acting Director

National Cancer Institute